Related Experiment Video
Updated: May 3, 2026
11:28
Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays
Published on: February 9, 2022
2.8K
Therapeutic potential of Na(V)1.1 activators
Henrik S Jensen1, Morten Grunnet1, Jesper F Bastlund1
1Neuroscience Drug Discovery, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Copenhagen, Denmark.
Trends in Pharmacological Sciences
|January 21, 2014
Summary
Selective activators of the Nav1.1 sodium channel show therapeutic promise for neurological disorders like epilepsy and Alzheimer's disease. This approach targets specific inhibitory interneurons, potentially reducing toxicity risks associated with earlier sodium channel drugs.
Area of Science:
- Neuroscience
- Pharmacology
- Channelopathies
Background:
- Sodium channel inhibitors are established therapeutics, but activators face toxicity concerns.
- Nav1.1 sodium channels are crucial in inhibitory interneurons, unlike excitatory neurons with redundant channels.
Purpose of the Study:
- To propose Nav1.1 sodium channel activators as a novel therapeutic strategy.
- To explore the potential of targeting Nav1.1 for neurological conditions.
Main Methods:
- Review of existing literature on sodium channel function and pharmacology.
- Analysis of Nav1.1 expression patterns in neuronal subtypes.
- Discussion of drug discovery rationale and challenges.
Main Results:
- Nav1.1 channels are preferentially expressed in inhibitory interneurons.
- Selective Nav1.1 activation may offer a safer therapeutic window compared to broad-spectrum channel modulators.
Conclusions:
- Targeting Nav1.1 represents a promising, yet challenging, new direction for treating epilepsy, schizophrenia, and Alzheimer's disease.
- Further research is needed to identify selective Nav1.1 activators and validate their therapeutic efficacy and safety.
More Related Videos
Related Concept Videos
01:26Voltage-gated Ion Channels
11.2K
Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
11.2K
01:26Voltage-gated Ion Channels
7.6K
7.6K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K
01:15Cholinergic Receptors: Nicotinic
5.4K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.4K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.2K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K